

Unparalleled Pharmaceutical Coverage on Dialog[®] and DataStar[™]

3 New on DataStar[™] —
Cochrane Database of
Systematic Reviews

3 New Healthcare Newsletters
Database Now on DataStar[™]

8 New Swiss Company
Financials Database Available
Exclusively on DataStar[™]

Most of our users would agree that Dialog and DataStar's pharmaceutical coverage is unparalleled. But what is it exactly that makes our pharmaceutical offering so powerful?

Over the years we have worked hard to give you all the sources you need on a day-to-day basis and also to ensure that this collection is well rounded and addresses all areas of drug information. For this issue of the *Chronolog*, we have selected a number of key sources and publishers with a view to showing you what we have achieved. Look for contributions about:

- Drug pipeline products (from Pharma-projects and IMSworld R&D Focus)
- Drug reference material (from Martindale — The Complete Drug Reference)
- Patent literature (from Derwent and IMS Health)
- Congresses and Symposia (from Prous Science Daily Essentials)
- Clinical Trial Evaluations (from Adis Clinical Trials Insight)
- Full-text pharmaceutical news sources on Dialog and DataStar
- Comprehensive drug research source (from EMBASE[®])
- Market research from Profound ResearchLine

For an exhaustive list of pharmaceutical sources available on Dialog and DataStar we recommend you consult the 2001 *Worldwide Database Catalog* or visit our web site at <http://library.dialog.com/dbcat/>.

We are pleased to announce the launch of two new databases on DataStar this

September related to pharmaceuticals, also reviewed in this issue:

- Cochrane Database of Systematic Reviews (CDSR)
- NewsRx (RXNS)

The loading of Cochrane Database of Systematic Reviews (CDSR) introduces Evidence-Based Medicine (EBM) as new and unique content on DataStar and is in recognition of the growing importance of EBM internationally. CDSR has been frequently requested by our customers, and we hope that you will be pleased that this file is now available. NewsRx (RXNS), from CW Henderson, offers 20 healthcare newsletters organized along therapeutic areas and complements our other news sources (from PJB, Adis, IMS and others).

As an information professional, you need to know that you offer your company the best possible content and that you facilitate its decision making in all areas of research, product development, marketing and competitor analysis. As a Dialog or DataStar user, you are in the best position to do this, not only on the basis of our content, but also because our powerful search tools help you cut through the mass of pharmaceutical information added to our services every day.

Of course, if you have any questions regarding Dialog or DataStar content or search features, our experienced Knowledge Center staff is here to help. If you have any comments for us in the pharmaceutical and healthcare content area, please send us an e-mail to customer@dialog.com. ♦

Don't miss the Pharmaceutical Forum

September 11, 2001, 8am – 4pm

Woodbridge Hilton, Iselin, New Jersey

Register and learn more about this
Forum and other Update sessions at

<http://www.dialog.com/events/update/>

Table of Contents

From the Editor 2
 Bluesheets/Datasheets 2
 Trade Shows 2

What's New

New on DataStar™ — Cochrane Database of Systematic Reviews 3
 New Healthcare Newsletters Database Now on DataStar™ 3
 New Swiss Company Financials Database Available Exclusively on DataStar™ 8
 PIRA Management and Marketing Abstracts Now Available on Dialog® 9
 Pharmaprojects on DataStar™ Now Includes Images and New Quick Codes 10
 Market Research from Profound® ResearchLine 10
 DIOGENES® Reloaded with New Fields 11
 Martindale Reloaded on DataStar™ 14
 Mergent Files Available Soon on Dialog 15
 CANCERLIT® Reloaded 15

Content Update

Unparalleled Pharmaceutical Coverage on Dialog® and DataStar™ 1
 Recent and Relevant Congress Coverage in Prous Science Daily Essentials 4
 Adis Clinical Trials Insight: the New, Improved LMS Drug Alerts 4
 IMSworld Files on Dialog® and DataStar™ 5
 EMBASE® for Current and Comprehensive Drug and Medical Research 6
 Focus on Pharmaceutical News Sources 7

Training Update

Using BizInt Smart Charts to Organize Your Pipeline Data 9
 Pharmaceutical Patent Searching in Derwent Databases 12
 Training Schedule 16

From the Editor

The theme for the September *Chronolog* is pharmaceuticals and healthcare. Dialog has an extensive collection in this area.

Highlighted in this issue are articles providing information about content and search tips from a number of important databases used by pharmaceutical searchers: Prous, IMSworld, Adis, Derwent, and Elsevier.

In addition, Dialog®, DataStar™, and Profound® continue to add content in other subject areas. See stories about new business databases

on Dialog and DataStar and enhancements to other files as a result of reloads.

Finally review the schedule below for Regional Updates so you can attend one near you.

Sep 13, Toronto	Oct 12, New York City, NY
Sep 20, Columbus, OH	Oct. 23, San Francisco, CA
Oct 10, Boston, MA	Oct. 25, Los Angeles

Don't forget to check the online version of the *Chronolog* at <http://library.dialog.com/chron/2001/0009> for additions to some of the articles in this issue. ♦

Dialog Bluesheets / DataStar Datasheets

This new or revised documentation is available in the Dialog Library at <http://library.dialog.com/bluesheets>. Users can also consult Dialog Bluesheets™ (File 415).

New or revised DataStar documentation is available at <http://library.dialog.com/datasheets>. Users can also consult the DataStar file BASE—DataStar Database Guides.

File 249 PIRA Management & Marketing Abstracts

SWFR Worldbox Swiss Company Financials

File 555 Mergent™ Company Profiles

DIOG DIOGENES® FDA Regulatory Updates

File 556 Mergent™ Company Snapshots

CDSR Cochrane Database of Systematic Review

File 557 Mergent™ Company News Reports

MART Martindale: The Complete Drug Reference

Trade Shows

We will see you there!

September 19-22 Aboard the Oriana
Marketing Forum U.K.

November 6-8 Pasadena, CA
Internet Librarian

November 12-13 Santa Clara, CA
E-Content 2001

Chronolog®

The *Chronolog* (ISSN 0163-3732) is published by:

The Dialog Corporation
 11000 Regency Parkway, Suite 10
 Cary, North Carolina 27511 USA.

1.800.334.2564 or 1.919.462.8600
 Fax: 1.919.468.9890

Please address any comments or questions to customer@dialog.com.

DIALOG is a service mark of The Dialog Corporation registered with the U.S. Pat. & Trademark Office. Chronolog, DIALINDEX, DIALOG, DIALOG OnDisc, DialogLink, DIALORDER, First Release, OneSearch, ONTAP, and Profound are trademarks registered with the U.S. Pat. & Trademark Office. DataStar, DIALOG Headlines, DIALOG Homebase, DIALOGSelect, SourceOne, and SitePrints are service marks of The Dialog Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders. The contents of this publication are not copyrighted and may be freely reproduced.

New on DataStar™

Cochrane Database of Systematic Reviews

Summer 2001 saw the launch of the Cochrane Database of Systematic Reviews (label: CDSR) on DataStar.

In today's world, healthcare professionals, consumers, researchers and policy makers are faced with an unmanageable amount of information. The Cochrane Collaboration was formed in response to this problem. This grouping bears the name of Archie Cochrane, a British epidemiologist, who first called attention to the collective ignorance about the effects of healthcare, and recognized that the people who need to make informed decisions do not have ready access to reliable reviews of evidence-based research. The Cochrane Database of Systematic Reviews is the premier resource in Evidence-Based Medicine (EBM)—one of the fastest-growing areas of medical interest.

The international collaborative effort that was founded in response to Cochrane's agenda has created a body of people with a vast collective knowledge that systematically reviews randomized, controlled trials. Key elements of these reviews are not just that they bring together available research, but that they are done systematically and kept up-to-date. In this way, not only will users always have the latest information, but also planning for new research will be well informed and researchers and funding bodies will not miss promising leads or embark upon studies asking questions that have already been answered.

The Cochrane Collaboration has evolved rapidly, but the basic principles have remained the same. It is an international organization built on nine core values:

- collaboration
- enthusiasm of individuals
- avoiding duplication
- minimizing bias
- keeping up-to-date
- ensuring relevance
- ensuring access
- continually improving the quality of its work
- continuity

There are over 50 contributing review groups, and they cover most of the important areas of healthcare; new groups continue to be added. The members of these groups—researchers, healthcare professionals, consumers, and others—share an interest in generating reliable, up-to-date evidence relevant to the prevention, treatment, and rehabilitation of particular health problems or groups of problems. Examples of questions members consider are: How can stroke and its effects be prevented and treated? What drugs should be used to prevent and treat malaria, tuberculosis and other infectious diseases? What strategies are effective in treating brain and spinal cord injury and its consequences, and what rehabilitative measures can help those with residual disabilities?

The database comes in two parts: the summaries file (label: CDSR — available on all DataStar platforms) and the full reviews which can be accessed via DataStarWeb only. Access to these full reviews is from

CDSR, where a link is embedded in each summary document. Clicking the link will take you to the full review, which is presented as a PDF document.

Each full review incorporated in the database consists of:

- a 'cover sheet' giving the title and citation details; names and contact details of the reviewers; and the sources of support for preparing the review
- a structured abstract
- discussion of the results of the analysis
- implications for practice and research
- full citations to reports of studies included and those considered in the review but not included
- tables of the characteristics of the studies in the review, including information relevant to an assessment of the methodological quality of each of the studies
- tables and graphs of the results of the review, with presentation of the statistical syntheses (meta-analyses), when these were both possible and appropriate ♦

New Healthcare Newsletters Database Now on DataStar™

A new health news database, News RX (DataStar label RXNS) was launched on DataStar this summer. This database is a valuable and unique addition to DataStar and complements and extends our existing healthcare news coverage.

RXNS contains approximately 20 healthcare newsletters, uniquely organized around therapeutic area, rather than industries, companies and products, as other newsletters tend to be. Articles are compiled from stories in quality newspapers, peer-reviewed journals, conference reports, news releases, and articles sourced from other health and medical organizations. Titles include: *AIDS Weekly*, *Biotech Week*, *Cancer Weekly*, *Drug Week*, *Gene Therapy Weekly*, *Genomics & Genetics Weekly*, *Health & Medicine Week*,

Heart Disease Weekly, *Hepatitis Weekly*, *Immunotherapy Weekly*, *Obesity*, *Fitness & Wellness Week*, *Pain & Central Nervous System Week*, *TB & Outbreaks Week*, *Vaccine Weekly*, *Women's Health Weekly* and *Medical Letter* on the CDC & FDA.

NewsRX was founded 16 years ago and serves top professionals in over fifty countries worldwide. The newsletters are used by healthcare providers, pharmaceutical and biotechnology companies, universities, doctors and nurses, news services and research institutes.

RXNS provides answers to wide ranging questions such as:

- What are the latest developments in anaesthesia?

Continued on page 9

Recent and Relevant Congress Coverage in Prous Science Daily Essentials

Coverage of recent and ongoing congresses and symposia is a unique feature of the Prous Science Daily Essentials drug news files on Dialog (Files 458, 459) and DataStar (PRED, PREC, PRES). This information is easily retrieved by searching on Publication Type (PT=Congress) in DataStar or Document Type (DT=Congress) in Dialog.

With the Prous Science Daily Essentials, it is also easy to retrieve information on new pharmaceutical compounds that have been publicly described for the first time. This is done by searching on the Status (ST) field in Files 458, 459 or the Scope (SC) field in PRED/PREC/PRES. A search for records with Status/Scope=New Compound and Publication Type/Document Type=Congress is a powerful tool for obtaining information on new drugs that have not previously appeared in the biomedical literature. Refer to the Dialog Bluesheet at <http://library.dialog.com/bluesheets> and the DataStar Datasheet at <http://library.dialog.com/datasheets> for search tips.

File 458 and PREC contain records published in the most recent four weeks. For example, the more than 130 citations to

congresses and symposia found in the Prous Science Daily Essentials current files during the first week of July 2001 were to meetings in such diverse biomedical arenas as chemotherapy, headaches, diabetes, neurology, hypertension, rheumatism, heart failure, transplantation and gene therapy (See Table 1 in the online version of the September *Chronolog*). The majority of these 130+ records provides new results from experimental or clinical trials for previously known compounds; however, adding the New Compound constraint to the search criteria retrieves a core set of 25-30 records — many with chemical structure images — describing heretofore unknown compounds, some of which are postulated to have a novel mechanism of action (See Table 2 in the online version of the September *Chronolog*).

The Prous Science Daily Essentials files, which are updated daily, excel at providing this sort of “mission-critical” knowledge to the pharmaceutical industry in a timely fashion and with search options that facilitate the

retrieval of specific information types.

Options for the Status/ Scope search field are New Compound, Licensing Opportunities, Line Extensions, New Approvals, and New Launches; Document Type/ Publication Type search criteria are Congress, Patent, Current Literature, Company Communication, and Quarterly/Semi-Annual/ Annual Reports. It is also possible to search for records by broad (e.g., Cardiovascular Drugs) or narrow (e.g., Antihypertensive Drugs) therapeutic categories.

And, every drug cited in the Prous Science Daily Essentials current files on Dialog and DataStar has an associated identifier (Prous Science Entry Number) that can be used to search in the archival Daily Essentials files (F45/PRES) or other Prous Science files (Drugs of the Future, F453/PRFU; Drug Data Report, F452/PRDR) for additional information, such as a product monograph

and scheme of synthesis (F453/PRFU) or exhaustive patent and literature references (F452/PRDR). ♦

Coming soon to DataStar:
Images in PRDR!

Images of drug structures will soon be included in PRDR— Prous Science Drug Data Report.

Adis Clinical Trials Insight on DataStar™: the new, improved LMS Drug Alerts

Since 1983, Adis LMS Drug Alerts has been a valued source of highly structured evaluations of key papers from the international medical and biomedical journals on drugs, drug therapy, adverse drug reactions and pharmacoeconomics.

Now Adis is relaunching LMS Drug Alerts with a new title: Clinical Trials Insight (CTI) (label: ACTI) and a number of major improvements. These are:

Content-related

- Full-text structured assessments appear in all records (only 15% of the records in

LMS Drug Alerts have assessments)

- All clinical and volunteer studies are covered

Search-related

- Search clinical relevance ratings
- Search evaluation scores
- Search phase of study
- Search type of study design
- Search study control

Unique in the field, Clinical Trials Insight puts you on the inside track with the latest clinical trial results with expert evaluation from informed Adis scientists. A CTI search

will provide you with invaluable information in your therapeutic area on trial results, clinical significance, product applications and cost analysis — facts that would normally take extensive research to compile and analyze. From efficacy, tolerability and pharmacoeconomic outcomes to trial design score, clinical relevance ranking and key study messages, CTI provides the uniform measures needed to assess the reliability and applicability of today’s clinical trial results. Acknowledged experts in clinical trial monitoring, Adis scientists review the best evidence from more than 1,700 peer-reviewed biomedical publications — providing the pertinent information from timely and groundbreaking studies.

Continued on page 11

IMSworld Files on Dialog® and DataStar™

Files provided by IMSworld Health can provide executive insight to the pharmaceutical industry.

In this article we explore how the IMSworld files can help with:

- Competitor Intelligence
- Licensing
- Mergers & Acquisitions

The IMSworld files referenced in the article are:

- Pharmaceutical Company Profiles (Dialog File 449; DataStar File IPCP)
- Product Launches (Dialog File 446; DataStar File IPLL)
- R&D Focus (Dialog File 445; DataStar File IPUR)
- Patents International (Dialog File 447; DataStar File IPIP)
- Product Monographs (Included in Dialog File 446: Product Launches; DataStar File IPOP)

Competitor Intelligence

The foundation for evaluating a competitor and its product line is a thorough sales analysis. Overall company sales, both recent and historic, can be broken down by country to determine areas of greatest geographic strength and growth by therapeutic class to see in which drug classes they are most active. A more detailed product analysis can reveal underlying portfolio strengths or weaknesses and their relative position or market share within a therapeutic area. Different observers consider different measures—some want to see sales by value, some want sales in units, and others want to see number of prescriptions. This type of analysis is available in *Pharmaceutical Company Profiles* (F449/IPCP).

Check for new drugs coming to the market via *Product Launches* (F446/IPLL) if your company's share of existing products is to be protected.

In addition to evaluating the performance of products already launched, the company's development program is also significant. Some quantitative and evaluative information on products in research via

R & D Focus (F445/IPUR) shows which therapy classes the company is concentrating on, and which new drugs it will bring to the market in the near and medium term.

Completing the picture, a look at the company's patent portfolio through *Patents International* (F447/IPIP) shows how vulnerable the company is to generic competition, as the patents of its products reach their expiration dates.

Analyzing the key components of a company including its strategy, financials, and corporate structure, using *Pharmaceutical Company Profiles* (F449/IPCP), is helpful in putting all this competitive information into context.

Licensing

A pharmaceutical company often enters into an agreement with another company to answer a short or medium term need.

For example, a company seeking to bolster its R & D portfolio may want to try to identify early stage drugs it would consider out-licensing and make a proactive approach. This information can be found in *R & D Focus* (F445/IPUR). If the company is seeking later stage drugs, it can research another company's existing product portfolio including line extensions through *Product Monographs* (F446/IPOP). It can then contact that company with a view to exploratory discussions. The value of a drug in particular geographic markets is also related to the length of the patent term before expiration; you can check this in *Patents International* (F447/IPIP).

Alternatively, a company may invent a drug that it realizes has significant commercial potential, but that does not fit in with its overall strategy. Both the company licensing the drug, as well as its prospective licensee will want to know the worth of the drug within the disease areas for which it is indicated so that the royalty arrangements are favorable. This type of information is available in *Pharmaceutical Company Profiles* (F449/IPCP).

Mergers and Acquisitions

The corporate decision to merge or acquire a company is usually made as part of the strategic planning process. The decision is taken after as much supporting information as possible has been obtained and evaluated.

The candidate may have products in similar or complementary therapy markets that will strengthen the acquiring company, or it may pose a competitive threat that the acquiring company can overcome by joining forces with it. Whatever the rationale, the acquiring company initially needs to undertake a more global approach to identifying suitable targets to find out their overall global positions, main revenue drivers and therapeutic class involvement, as well as their strengths or weaknesses in the main geographic area. Once this top line analysis is complete and key strategic areas of fit are identified, a more detailed breakdown on sales in specific therapeutic areas and their existing product portfolio can be undertaken.

An evaluated analysis on how the company measures up at three critical stages of the product life cycle is available via IMSworld life cycle files; *R & D Focus* (F445/IPUR), *Product Launches* (F446/IPLL) and *Patents International* (F447/IPIP). A company's ability to innovate, launch drugs and protect its intellectual property gives a further dimension to its suitability as an M & A target. Understanding the candidate's overall strategy through pharmaceutical company profiles and its fit with the acquiring company, is vital in the case for the acquisition. Surrounding the picture of the candidate's present situation is its history to date, since it shows how previous decisions have contributed to its actual competitive position.

Searching IMSworld files can help you at every stage of the product life cycle. Full details about these files can be found in the Dialog Bluesheets and DataStar Datasheets or by contacting Dialog Knowledge Center at 800-3-DIALOG (334-2564). ♦

EMBASE® for Current and Comprehensive Drug and Medical Research

EMBASE (Dialog Files 72, 73; DataStar Files EMED, EMZZ), produced by Elsevier Science, has long been renowned as an excellent resource for bibliographic searching in biomedicine and pharmaceutical literature. A number of changes and enhancements over the past several years have added to the database's value as an essential drug research tool. (See the online version of the September *Chronolog* at <http://library.dialog.com/chron/2001/0009> for facts and figures about EMBASE.)

EMTREE, the EMBASE thesaurus

EMBASE records are indexed with subject headings from the EMTREE thesaurus, a collection of over 42,000 drug and medical preferred terms (descriptors), organized in a cascading tree structure that ranges from broad concepts (e.g., *chemicals and drugs*) to very specific terms (e.g., *prednisolone acetate*), represented by 10,000 tree codes. In addition, EMTREE contains over 180,000 synonyms as added entries to preferred descriptor terms; synonyms include:

- Various drug generic nomenclatures (whenever possible, drugs are indexed in EMTREE with International Nonproprietary Names) — USAN, BAN, etc.

- Chemical compound names
- Laboratory codes
- CAS® Registry Numbers (also searchable in the RN= field and in the RN paragraph)
- Drug product names, registered trademarks, etc.
- Variants of disease names
- MeSH subject headings from the U.S. National Library of Medicine

EMTREE terms can be exploded to retrieve narrower, more specific terms within subject hierarchies (e.g., *s antineoplastic agent#*). EMTREE can be accessed online via the EXPAND command. The online thesaurus shows preferred terms (descriptors), synonyms, broader and narrower terms, and EMTREE codes. On Dialog, it is especially useful for retrospective searches on drugs, as old and replaced drug names (displayed as synonyms) are listed along with current names; they can be searched together when comprehensive retrieval is necessary. (See Example 1)

The online thesaurus lets Dialog and DataStar searchers retrieve additional records indexed to old or changed names (listed as synonyms) that would be missed by searching the preferred term alone.

CAS® Registry Numbers

EMBASE has Chemical Abstract Service Registry Numbers for about 14,000 substances in EMTREE. They are directly searchable in the RN field (e.g., *s rn=30516-87-1* on Dialog or *30516-87-1.RN.* on DataStar). Before the recent EMBASE reloads, they only retrieved records added from 1988 forward; they now work across the entire database, back to 1974.

CAS Registry Numbers are included as synonyms in EMTREE, and are available in the online thesaurus via EXPAND as pointers to preferred EMTREE drug names:

```
?e (rn=30516-87-1)
Ref Items Type RT Index-term
R1 10180 1 *RN=30516-87-1
R2 10482 S 25 ZIDOVUDINE
```

Routes of drug administration links

For over a decade, EMBASE indexers have qualified EMTREE terms with drug and disease “links,” or subheadings, that identify very specific aspects of subjects and allow great precision in query building (e.g., *diazepam (link) adverse drug reaction*). In 2000, an additional 47 links identifying specific routes of drug administration were added; for example, *diazepam (link) oral drug administration*. These subheadings are assigned by indexers to identify both novel and routine routes of administration; if the route is a significant aspect of the article (for example, a novel route), the term *drug administration* is also linked to the drug name. See the online version of the September *Chronolog* at <http://library.dialog.com/chron/2001/0009> for a list of link subheadings for routes of drug administration. DataStar searchers can display a list of all link subheadings online with the command *..D SH (display subheadings)*.

Quick explodes on DataStar

Pre-defined clusters of headings have been created on DataStar for greater convenience in searching related links together:

```
?e (allegra)
Ref Items Type RT Index-term
R1 101 1 *ALLEGRA
R2 405 U 10 FEXOFENADINE

?e r2
Ref Items Type RT Index-term
R1 405 10 *FEXOFENADINE
R2 49695 DC=D16.390.10.10 (HISTAMINE H1 RECEPTOR ANTAGONIST)
R3 49695 DC=D24.20.390 (HISTAMINE H1 RECEPTOR ANTAGONIST)
R4 1952 B 144 HISTAMINE H1 RECEPTOR ANTAGONIST
R5 101 S 1 ALLEGRA
R6 0 S 1 FEXOFENADINE HYDROCHLORIDE
R7 8 S 1 MDL 16455
R8 4 S 1 MDL 16455A
R9 46 S 1 TELFAST
R10 0 S 1 2 (4 (1 HYDROXY 4 (4 (ALPHA HYDROXYBENZHYDRYL)
R11 394 S 1 RN=138452-21-8

?s r1 or r5:r11
405 FEXOFENADINE
407 ALLEGRA:RN=138452-21-8
S1 418 "FEXOFENADINE" OR R5:R11
```

U = use (preferred term)

B = broader term

S = synonym

Example 1

Note: THES ALLERGRA will give a similar list of selectable terms on DataStar.

Continued on page 7

Focus on Pharmaceutical News Sources

The high stakes healthcare marketplace has spurred the development of many specialized news sources to serve the competitive intelligence needs of pharmaceutical companies and industry watchers. Databases assembled in the DIALINDEX®/OneSearch category PHARMIND and the DataStar CROS group 65 are good examples. Given the lengthy list of choices, selecting which resources to monitor on an ongoing basis can be challenging. What criteria can be used to single out the best news databases to match your own, and your company's, specialized research requirements? A comparative checklist might begin with examination of three basic characteristics in each

file: full-text accessibility, fast reporting, and subject focus.

Full-Text Accessibility. Ideally, an online news service will provide full-text articles for immediate display, not just citations and abstracts or summaries. In addition to meeting demands for rapid document delivery, full-text access in news files on Dialog and DataStar means that each keyword is separately searchable. This feature enables prescreening of newsletter contents for items of interest that may not be uncovered through perusal of article titles alone.

Speaking of titles, another aspect to examine when comparing each file's relative

accessibility is how informative are its records when viewed in short, browsing format? Cryptic titles are, alas, a hallmark of many industry news sources published in hardcopy format. The rationale behind this may be that, when viewing paper pages, readers automatically augment sparse leads by rapidly scanning opening sentences immediately below. Unfortunately, this characteristic does not translate well into the online environment. Users of Dialog Interactive Alerts, for example, rely on browsing titles alone to identify key content. In this context, it's difficult to judge relevance when a source typically relays only a company name in article titles or uses general headings such as "FDA in Brief" or "Legislative Roundup." This is

Continued on page 8

EMBASE — Continued from page 6

QX Quick Toxicology

Includes AE Adverse drug reaction
TO Drug toxicity
SI Side effect

QT Quick Therapy

Includes DT Drug therapy
RT Radiotherapy
SU Surgery
TH Therapy

QD Quick Diagnosis

Includes DI Diagnosis

Example:

```
1_: quinolone-derived-antiinfective-
agent# with qx
```

Clinical trial searching: Key descriptors

A special class of subject terms, called *descriptors*, are used to identify routinely-indexed concepts such as human and animal study types, patient sex and age, patient population size, item (document) types, etc. Of particular interest to pharmaceutical researchers, evidence-based medicine specialists, and others are descriptors for clinical trials and specific study designs:

- Clinical trial
- Phase 1 clinical trial
- Phase 2 clinical trial
- Phase 3 clinical trial
- Phase 4 clinical trial
- Meta analysis

- Randomized controlled trial
- Double blind procedure
- Single blind procedure
- Crossover procedure
- Multicenter study
- Controlled study

Note: Many of these are available as special options on DataStarWeb and DataStar for Windows—just click the box to select them.

The routine, consistent use of these terms according to specific guidelines ensures reliable retrieval for these study types.

Molecular sequence numbers

Biotechnology-related records now contain molecular sequence numbers; these identify accession numbers for sequences found in various databanks and repositories. It is helpful for searchers looking for information on novel therapeutics and related topics.

Nucleotide sequence numbers:

- GENBANK
- EMBL (European Molecular Biology Laboratory)
- DDBJ (DNA Data Bank of Japan)

Protein sequence numbers:

- SWISSPROT
- PIR (Protein Identification Resource)

This field contains both the databank name and sequence accession number (e.g.,

GENBANK AA 262366). It is available on both Dialog and DataStar:

```
Dialog s sq=aa230649
DataStar 1_: aa230649.ds.
```

EMBASE Alert

EMBASE Alert (Dialog File 172; DataStar File EMBA), a companion database to EMBASE, is a "rolling" file that contains the most current eight weeks of in-process EMBASE data — bibliographic citations and abstracts that have not yet undergone subject indexing. Making database records available online 5 to 10 days earlier than EMBASE, it is a valuable tool for current awareness on hot and newsworthy topics.

Because EMBASE Alert has no subject indexing or coding, it can be searched easily with free text:

```
?s (sumatriptan or triptan?) and
(headache? or migraine? or
antimigraine?)
```

Learning more ...

Call the Knowledge Center at 800-3DIALOG (334-2564) for additional information on searching EMBASE. Elsevier Science holds free public training sessions on EMBASE; many of these sessions are held at Dialog offices. EMBASE is also covered in Dialog's Biomedical Information Seminar; see <http://training.dialog.com> for details. ♦

New Swiss Company Financials Available Exclusively on DataStar™

Worldbox Swiss Company Financials (DataStar label SWFR) from Graham Associates AG is now available exclusively on DataStar™.

SWFR is a financial database, providing extensive coverage in English, of Swiss and Liechtenstein registered companies, together with their parent companies and subsidiaries worldwide. Information is held on all companies who disclose financial details, including large, medium and small; quoted and non-quoted, and public and private firms.

All sectors of industry and commerce are covered. The database will be a valuable tool for anyone interested in researching both financial and directory-style information on Swiss companies. As there are no legal disclosure requirements in Switzerland, other than for public companies, most of the information in SWFR is collected through extensive research and interviews, providing for high quality, accurate information.

SWFR is also competitively priced, with connect time charges of only CHF 130.00 (USD 90.00) and a full record cost of CHF 60.00 (USD 41.38).

Use SWFR to:

- find detailed financial information on a specific company
- identify companies of which a named individual is a director
- find the names of a specific company's bankers and auditors
- find answers to such detailed questions as 'which pharmaceutical companies formed after 1990 have sales of over CHF 100 million?'

Approximately one-third of the records in SWFR has Profit and Loss and Balance Sheet information. Most of the remaining records contain key financials, with a small proportion containing directory details only.

Search Tips

In order to ensure that you retrieve only those records which have, for example, both Profit and Loss and Balance Sheet data available, search as:

```
1_: BS=AVAILABLE and PL=AVAILABLE
```

Or enter ..ROOT followed by the field label and = to check availability of information. For example, to select only those records which have Number of Employees available search:

```
1_: ..ROOT EM=
R1 12044 DOCS EM=AVAILABLE
R2 1439 DOCS EM=NA
2_: R1
```

The complete database search guide is available in BASE, search BASE-SWFR. The online datasheet is available at: <http://library.dialog.com/datasheets>. ♦

Focus — Continued from page 7

why it's important to investigate whether a news source offers informative titles.

Databases such as **Business and Industry™** and **Gale Group PROMT®**, which routinely supplement sparse titles with keywords and phrases to enhance accessibility, are, in consequence, popular choices for Alerts.

Yet another factor to take into account when gauging relative accessibility is whether a database provides value-added indexing. For example, in files where company names are systematically identified in a separately searchable field in each record, Alert results will be much more precise. If you plan to monitor company names that contain common keywords, such as "gene therapy," "home diagnostics," and the like, relying on retrieval of words embedded in text, versus separate indexing, can produce many irrelevant results. Resources such as **Proux Science Daily Essentials** and **IMSworld R&D Focus Drug News**, each with systematic company indexing, are good choices for current awareness searches involving potentially ambiguous corporate names.

Controlled indexing of other factors can also be critical in news database selection. For example, both **Proux Science Daily Essentials** and **IMSworld R&D Focus Drug News** offer drug therapeutic category indexing using predictable terminology. In contrast, Alert strategies constructed to monitor developments related to specific indications (cardiomyopathy, diabetic nephropathy) or more general conditions (heart disease, renal disorders) must, in text-only files, include multiple synonyms. Consistent "event" (e.g., line extensions, licensing opportunities) and "concept" indexing (market share, market size, sales, consumption) is also a bonus in several news files, including **Business & Industry** and **Gale Group** databases.

Fast Reporting. Delving into the second of our basic selection criteria, fast reporting, requires more than a quick comparison of update frequency. What is the lag time between public availability of information and online dissemination in a given source? Does e-publication coincide with printed issue release, precede hardcopy, or, perhaps,

lag behind due to a moratorium policy? Some databases, such as **PHIND**, **Adis Newsletters**, and **Espicom Pharmaceutical & Medical Device News**, provide previews of articles days before their publication in hardcopy counterparts.

Industry news sources may be updated daily, weekly, biweekly, or monthly. In general, daily updating is an indicator of more up-to-date reporting. Good spot tests to assess time lag are quick searches to check when news of an important new drug approval or company merger first appeared in various resources.

Subject Focus. Last but not least, candidates for current awareness monitoring require careful scrutiny for subject focus or "slant." Competitive intelligence in the pharmaceutical industry involves tracking developments on both the scientific and commercial fronts. No single source is likely to cover all aspects equally well. For notes highlighting subject strengths in key full-text industry news resources, see the online version of the September *Chronolog* at <http://library.dialog.com/chron/2001/0009>. ♦

PIRA Management and Marketing Abstracts Now Available on Dialog®

This month we welcome PIRA Management and Marketing Abstracts (File 249) to the Dialog system. Providing coverage of all aspects of management and marketing practice and customer and industrial relations in the single European market and worldwide, File 249 is your source for abstracts on a wide range of topics in this field.

With coverage from 1996 to the present and weekly updates, this database, produced by PIRA International, will keep you up to date on the latest trends in management and marketing around the world. Relevant items from 200 journals, newspapers, books, and reports from the U.K., the U.S., and Europe are abstracted. All abstracts are in English, regardless of the original language of the

abstracted article. File 249 is the online equivalent of the monthly abstract journal *Management and Marketing Abstracts*.

Subject coverage includes:

- Management and change
- Organization and administration
- Production management
- Industrial relations
- Education and training
- Sales
- Physical distribution
- Corporate planning
- Economics ...and more.

Use PIRA Management and Marketing Abstracts to:

- Review ideas regarding international management

- Understand more about the importance of branding
- Find out the latest practices in human resources
- Learn about hiring processes
- Discover how the Internet has impacted production management, purchasing, and other areas

Search tips. Key fields in File 249 include: Company Name (/CO, CO=), Section Heading (/SH, SH=) and Journal Name (JN=). Search CO= or /CO with SH= or /SH to find records for a specific company with a particular subject heading, e.g., SELECT CO=BBC? AND SH=ADVERTISING?

Cost of searching PIRA Management and Marketing Abstracts is \$5.50/DialUnit and \$2.15 per full record. The Bluesheet for File 249 can be found on the Dialog web site at www.dialog.com. PIRA is also available on DataStar as file MMKA. ♦

Using BizInt Smart Charts to Organize Your Pipeline Data

As an experienced information specialist knows, the results of many patents and drug pipeline searches can result in “too much of a good thing.” Searches such as “What patents have been issued in this area?” or “What is our competitor’s pipeline?” can yield hundreds of records. The challenge is to organize this information to meet each reader’s needs.

BizInt Smart Charts products from BizInt Solutions provide tools to organize, analyze, present, and distribute valuable patent and drug pipeline data available on Dialog and DataStar. You can easily import your search results from Dialog or DataStar into BizInt Smart Charts, customize the presentation to meet your needs, and create a polished report for printed or electronic distribution—in a few minutes rather than the hours required to produce such reports manually.

BizInt Smart Charts for Pharmaceuticals creates tabular reports combining information from the leading drug pipeline databases. You create reports by importing your search results from Dialog or DataStar into BizInt

Smart Charts for Pharmaceuticals, which automatically processes the records and creates the chart. BizInt Smart Charts for Pharmaceuticals also provides an interface for searching pipeline databases on DataStar. Reports include the table and supporting records, and can be updated and combined with other BizInt Smart Charts reports. You can also add your own columns for comments and keywords.

Since coverage of therapeutic areas and compounds varies between databases, combining information into a single table helps you build a more complete drug pipeline report. BizInt Smart Charts for Pharmaceuticals is based on a detailed understanding of the structure and content of drug pipeline databases. Common fields (such as phase of development) are displayed in the same column to help the researcher compare information among databases.

BizInt Smart Charts for Patents provides similar capabilities for creating tabular reports from selected patent and scientific

Continued on page 14

Healthcare Newsletters — Continued from page 3

- What conditions are associated with copper deficiency?
- What can be done to reduce Hepatitis C transmission to neonates from infected mothers?
- What is the name of the newly identified hormone regulated gene?

The database has an archive back to 1997 and is updated weekly.

There are two types of articles — those aimed at consumers and those aimed at healthcare professionals. You may narrow your search to a particular article type by using the article type (AT) paragraph:

1_: Professional.AT.

You can also focus your search by qualifying your search term to the descriptor (DE) paragraph:

2_: Diabetes.DE.

For more information on RXNS see BASE — search BASE-RXNS. ♦

Pharmaprojects on DataStar™ Now Includes Images and New Quick Codes

Pharmaprojects is a leading source of global business intelligence on drugs in research and development and provides users with a comprehensive view of product development.

DataStar is pleased to announce the addition of structure images, as well as a series of enhanced quick codes to facilitate identification of major changes to documents held in Pharmaprojects.

Chemical structure images


Pharmaprojects provides details of each individual drug or formulation in the form of product profiles. In August, Pharmaprojects on DataStar was enhanced with the addition of over 11,000 chemical structure images to accompany many of the product profiles. These structures are available only through DataStarWeb™.

Netscape 4.0 (or above) is the optimal browser for image viewing on DataStar, but the structures may also be viewed via Internet Explorer 4.0 (or above). The images can be saved in HTML and also printed. For step by step instructions on saving and printing images, simply click on the Help button on DataStarWeb.

Records with images do not cost any more than those without. However, if you use DataStar Classic or DataStar for Windows, you will not be able to view the images, as they are only accessible via a web browser.

An example of a Pharmaprojects chemical structure image is given below:

You may, if you wish, restrict your searches to include only those documents with images, by selecting "Restrict to – documents with images" on DataStarWeb. You can also choose to display the images in a sec-



ond browser window or embedded in the document by clicking the Options button.

Major change quick code

This latest reload of Pharmaprojects on DataStar also brings an enhancement to the major change quick code. Three new quick codes concerning major changes to documents have been introduced:

MAJOR=YES

MINOR=YES

NEW=YES

These codes allow for greater specificity in searching, enabling you to look for product profiles which are new (NEW=YES) or have undergone a major change (MAJOR=YES). You may also select only those records which have undergone a MINOR change using the MINOR=YES quick code. Previously, only the quick code MJ=YES was available, which selected both NEW and MAJOR change records. The MJ=YES quick code is now a synonym for MAJOR=YES and so will select MAJOR change records only. In all cases, MAJOR, MINOR and NEW refer to the **latest change made to the record**.

You may also incorporate the major change limit into your searches, which allows you to reduce or limit a set of records to include only those which have undergone a major change, or are new within a specified time period. For example, to find product profiles which include Oedema as an indication and which underwent a major change, or were new, between June 1, 1999 and June 1, 2000 search as:

1_: OEDEMA.IN.

2_: ..L 1 MJ WL 19990601,20000601

or to search for those records which underwent a major change or were new after March 1 of this year, search as:

3_: ..L 1 MJ>20010301

Recently added enhancements to Pharmaprojects on Dialog and DataStar

This year Pharmaprojects has brought in a range of fully-browsable enhancements that

guarantee more precise searching and offer greater flexibility and variety to users' search criteria. These enhancements were described in the June *Chronolog*. (see page 4) Images for Pharmaprojects are also now available on Dialog (Files 128/928). Consult the Bluesheet for further information.

For a brief summary of the enhancements, see the online version of the September *Chronolog* at <http://library.dialog.com/chron/2001/0009>. ♦

Pharmaceutical Market Research from Profound® ResearchLine

Profound ResearchLine offers in-depth pharmaceutical market research data and is one of the best sources for this sector. The reports cover the global pharmaceutical industry, extending into medical devices and diagnostics. Some of the biggest names in market intelligence are represented including:

- PJB Publications
- Theta
- Datamonitor
- Frost & Sullivan
- Freedomia
- Reuters Business Insight
- Informa Global Pharmaceuticals & Healthcare
- Espicom Business Intelligence
- Business Communications Company
- Kalorama Information
- ATAC Strategic Insights

Profound is an invaluable source of information for marketing professionals, market researchers, competitive intelligence specialists, and account planners. To date over 6,500 up-to-date reports covering the pharmaceutical and healthcare sectors are available on Profound ResearchLine. Some of the publishers listed above are also available on Dialog and DataStar. ♦

DIOGENES® FDA Regulatory Updates Reloaded on DataStar™

DIOGENES FDA Regulatory Updates has been reloaded on DataStar. DIOGENES (DataStar file DIOG) is the most comprehensive source of information relating to the regulation of human drugs and medical devices by the US Food and Drug Administration (FDA). The database contains unpublished FDA documents acquired under the Freedom of Information Act which include Advisory Committee Minutes, Drug and Device Approval information, Regulatory Letters, Establishment Inspection Reports, and others. In addition the fulltext of several newsletters providing summaries of topical issues which affect health care and FDA-regulated industry are included.

DIOGENES has been reloaded and enhanced to include five new paragraphs:

1. PC — Product Category: includes the following terms: Drug, Device, Biologic, Veterinary, Food. *Search: DRUG.PC.*
2. AD — Address: The address of the Company named in the CO — Company name paragraph. *Search: MIAMI.AD.*
3. DE — Descriptors: Device classification, FDA Device code, Dosage form, Route of Administration and Keywords. *Search: ROUTE WITH INTRAVENOUS.DE. or DOSAGE WITH CAPSULE.DE.*
4. ST — Status: The date a drug or device application was submitted, the type of

submission for a device, the type of supplement for a device approval, FDA assigned code, the reason and date a drug has had approval withdrawn, the date a drug will no longer have marketing exclusivity and the substantial equivalence text. *Search: LABELLING ADJ CHANGE.ST. or 510K.ST.*

5. Notes (NT) — notes regarding a special situation with a document.

There is no change to the pricing.

Please refer to the online Datasheet at: <http://library.dialog.com/datasheets> or the complete database guide in BASE. Search BASE-DIOG. ♦

Adis Clinical Trials — Continued from page 4

If you are engaged in

- Product positioning
- Adverse event reporting
- Brand protection
- Clinical development
- Strategic planning
- Product assessment

then Adis Clinical Trials Insight can help you. Whether you are seeking clinical data to support an advantage for your drug or comparing studies to refute a competitor's claim, CTI ensures that critical information is only a keystroke away.

Let Clinical Trials Insight help you

- Learn how a new drug class performs in relation to existing agents
- Identify key specialists or researchers working with a specific drug
- Locate follow-up data and analysis on a specific trial or series of trials
- Pinpoint new markets for your drug in the treatment of related disorders
- Find evidence of a drug's effectiveness in a range of patient populations
- Assess key cost-effectiveness data for a drug in various work markets
- Track all significant safety reports for a drug.

Accompanying the improved content of CTI are a number of new improved search features that will help you pinpoint the information you need.

Expert Performance Rating. Adis evaluation of each study includes analysis of the positive and negative features of the study design and unique Adis ratings of the trial design - all combined to provide you with an essential uniform measure of study reliability, clinical relevance and marketing implications. This information is located in the Evaluation (EV) paragraph on DataStar.

Clinical relevance ratings can be searched using the following quick codes:

- CL=A (Study provides new evidence of clinical relevance)
 CL=B (Study provides supporting evidence to existing data)
 CL=C (Study adds no new or important information)

Evaluation scores are based on the adequacy of the data provided by the report and is a cumulation of the individual scores awarded to elements of the study design and conduct. The Limit command allows you to include only documents that fall within a particular evaluation score. Scores are categorized as:
 86 - 100 Excellent trial
 71 - 85 Good to very good
 50 - 70 Fair trial

< 50 Unacceptable trial or results require confirmation by a better designed study

Adis Comments provide insight on the development phase of a research drug, commercial drug information and strengths or limitations of the study design. You may also be directed to meeting abstracts and accompanying editorials relevant to the study. This information is searchable free-text.

Details of the study are presented within the main text of the document (paragraph TX on DataStar). The TX paragraph is searchable free text; the following quick codes have also been added to make it easier to pinpoint certain aspects of the study.

Details:	Quick Code:
Study Design:	SD=DOUBLE-BLIND
Study Control:	SC=PLACEBO-COMPARISON
Study Phase:	SP=PRECLINICAL
Study Endpoints:	SE=COMPLETE-CLINICAL-RESPONSE

Other search features in Clinical Trials Insight include searching by drug class, route of administration, patient criteria or author. Refer to the DataStar datasheet at <http://library.dialog.com/datasheets> or the DataStar Database of Databases (file label: BASE; search for BASE-ACTI) for a

Pharmaceutical Patent Searching in Derwent Databases

Helping to alert organizations to the latest developments

Derwent World Patents Index (Files 350, 351, 352)

Derwent's flagship product, the *Derwent World Patents Index*, is the most comprehensive, premium patent database in the world. *Derwent WPI* provides the searcher with unrivaled access to details of new pharmaceutical technologies, allowing organizations to conduct thorough searches for patents that may impact their R&D or patenting process.

The example below shows a search on *Derwent WPI* for foot and mouth diagnosis and helps to illustrate the value-added information contained within a *Derwent WPI* record. The example also shows how to set up and run an Alert for this search query, an automated search that is run each time that *Derwent WPI* is updated or monthly. Alerts are a low cost, current awareness tool and are the most effective way for any organization to monitor patent activities in a particular technology.

Before conducting a search, the searcher should set up the e-mail address to which the Alerts are to be sent. See the online version of the September *Chronolog* at <http://library.dialog.com/chron/2001/0009> to see how to set up an e-mail address.

Once an e-mail address has been set up, the searcher can conduct a search query. Here we have conducted a search for foot and mouth diagnosis in File 351.

```
?B 351
File 351:Derwent WPI 1963-2001/UD,UM &UP=200123
(c) 2001 Derwent Info Ltd

Set  Items  Description
---  -
?S FOOT(2W)MOUTH AND (DETECT? OR DIAGNOS?)

56939 FOOT
41980 MOUTH
298 FOOT(2W)MOUTH
715484 DETECT?
70780 DIAGNOS?
S1 44 FOOT(2W)MOUTH AND (DETECT? OR DIAGNOS?)
```

This search query resulted in 44 matching records. We continue the example by looking at the first of the matching records.

?T 1/9/1

The *Derwent WPI* record below includes the Derwent Enhanced Title and the Derwent Abstract, which is split up into clearly headed paragraphs, detailing the Novelty, Use and Advantage of the invention. It also includes other value-added information such as the Technology Focus paragraph and Derwent Class and Manual Code classifications.

```
1/9/1
DIALOG(R)File 351:Derwent WPI
(c) 2001 Derwent Info Ltd. All rts. reserv.

012988710
WPI Acc No: 2000-160563/200014
XRAM Acc No: C00-050077

Synthetic peptide used in protecting animals against Foot-
and-Mouth Disease Virus infections comprises a helper
```

```
T-cell epitope and a Foot-and-Mouth Disease Virus epitope
conjugate
Patent Assignee: UNITED BIOMEDICAL INC (UNBI-N)
Inventor: SHEN M; WANG C Y
Number of Countries: 087 Number of Patents: 004
Patent Family:
Patent No Kind Date Applicat No Kind Date Week
WO 9966954 A1 19991229 WO 99US13921 A 19990621 200014
AU 9948266 A 20000110 AU 9948266 A 19990621 200025
US 6107021 A 20000822 US 98100600 A 19980620 200042
EP 1089759 A1 20010411 EP 99931845 A 19990621 200121
WO 99US13921 A 19990621

Priority Applications (No Type Date): US 98100600 A 19980620
Patent Details:
Patent No Kind Lan Pg Main IPC Filing Notes
WO 9966954 A1 E 113 A61K-039/245
Designated States (National): AE AL AM AT AU AZ BA BB BG
BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU
ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT UA UG UZ VN YU ZA ZW
Designated States (Regional): AT BE CH CY DE DK EA ES FI
FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ
AU 9948266 A A61K-039/245 Based on patent WO 9966954
US 6107021 A C12Q-001/70
EP 1089759 A1 E A61K-039/245 Based on patent WO 9966954
Designated States (Regional): AT BE CH CY DE DK ES FI FR
GB GR IE IT LI LU MC NL PT SE

Abstract (Basic): WO 9966954 A1
NOVELTY - Synthetic peptide comprising a Foot-and-Mouth
Disease Virus (FMDV) epitope conjugate to a helper T-
cell epitope and optionally an immunostimulator sequence,
is new.
DETAILED DESCRIPTION - The synthetic peptide (I) is
selected from a group comprising:
NKYSASGSGVGRGDFGSLAPRVARQLPASFNXGAIK
(a) peptide fragments of the VP1 protein of FMDV
strains other than strain A12 and which are homologous
to the amino acids (aa) 134-168 of the A12 strain;
(b) a peptide having the consensus sequence derived from
the aa sequence of the FMDV VP1 protein from strains A,
O or Asia corresponding to aa 134-168 of the A12 strain;
(c) peptides having the sequence (ii)-(v); and
(d) peptides (i-iv) where the aa at positions 134 and 157
of the FMDV strain A12 VP1 protein are replaced by
Cys residues.
(i) KYX3GX3RGDX3LAXRVX3LPXSFNXGAX2;
(ii) X22QX3SFNXGAX2;
(iii) X2YX4VX3RGDX3LX3KX2RXLPX2FNXGAX;
(iv) X2YX4RRGDXXLAERXSX2LPTDFNYGAVK.
INDEPENDENT CLAIMS are also included for the following:
(1) a peptide comprising the aa sequence of a peptide in
(I) and an aa sequence of a helper T-cell epitope or of
a general immunostimulatory sequence;
(2) a structured synthetic antigen library where the
library consists of multiples of the amino acid sequence
selected from 9 amino acid sequences given in the
specification;
. . . .
ACTIVITY - None given.
MECHANISM OF ACTION - Vaccine.
USE - The peptide is used to generate an enhanced immune
response against a FMDV antigen in animals, e.g. farm
animals. It can also be used to diagnose FMDV infection
in a mammal.
ADVANTAGE - In contrast to previous vaccines the present
invention requires lower levels of biosecurity, has a
reduced loss of immunogenic activity, are less prone to
product instability and lot-to-lot variability and do
not need periodic revision due to antigenic variation
in the field.
```

```

pp; 113 DwgNo 0/4
Technology Focus:
TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Peptide: The
peptide is selected from the sequence KYASGSGV
RGDFGSLAPR VARCLPASFN YGAIK or homologous sequences
derived from the other strains of FMDV. The peptide may
further comprise 1-13 aa from either end of the 134-157
segment of VP1. The VP1 target sequence is selected
from one of 17 aa
. . . .
Title Terms: SYNTHETIC; PEPTIDE; PROTECT; ANIMAL; FOOT;
MOUTH; DISEASE; VIRUS; INFECT; COMPRISE; HELP; CELL;
EPITOPE; FOOT; MOUTH; DISEASE; VIRUS; EPITOPE; CONJUGATE
Derwent Class: B04; C06; D16
International Patent Class (Main): A61K-039/245; C12Q-001/70
International Patent Class (Additional): A61K-038/00;
A61K-039/00; A61K-039/12
File Segment: CPI
Manual Codes (CPI/A-N): B04-B04C; B04-C01G; B04-E02F;
B04-E03F; B04-F11; B12-K04A4; B14-G01; B14-S11; C04-B04C;
C04-C01G; C04-E02F; C04-E03F; C04-F11; C12-K04A4; C14-G01;
C14-S11; D05-C12; D05-H07; D05-H09; D05-H17
Chemical Fragment Codes (M1):
*01* M421 M431 M710 M782 M905 P434 P831 Q233 RA00NS-T
RA00NS-M RA00NS-N
*02* M421 M423 M431 M710 M782 M905 P434 P831 Q233
RA00H3-T RA00H3-M RA00H3-N
*03* M421 M431 M710 M782 M905 P434 P831 Q233 RA00H1-T
RA00H1-M RA00H1-N
Specific Compound Numbers: RA00NS-T; RA00NS-M; RA00NS-N;
RA00H3-T; RA00H3-M; RA00H3-N; RA00H1-T; RA00H1-M; RA00H1-N
Key Word Indexing Terms:
*01* 93605-0-0-0-CL, NEW 184616-0-0-0-CL,
NEW 184611-0-0-0-CL, NEW

```

Once the search query has been run, it is possible to set up the strategy as an Alert, so that the query is run automatically each time that the *Derwent WPI* is updated. The Alert can then be sent to you by postal mail or by e-mail. Not every update will contain records as in the following. Here, we have chosen to receive the Alert by e-mail:

```

?S S1 AND UB=9999
      44 S1
      8271 UB=9999
S2 0 S1 AND UB=9999
?PRINT S2/9/ALL ADDR ADDJONES
Address "ADDJONES" is used for E-Mail (Internet) delivery:
Internet address DCJONES@ALGO.COM
Do you want to use this address?
Y = Yes N = No
?Y
>>>No items to PRINT in set 2.
?SAVE ALERT FOOTM
"DDFOOTM" stored as a Weekly Alert in File 351.

```

The Alert will now run automatically with each update, so there is no need to spend time and resources conducting the searches manually. To have the Alert run only monthly, include the word "MONTH" in the SAVE command (e.g., SAVE ALERT MONTH FOOTM).

Besides *Derwent WPI*, there are two other Derwent files on Dialog with valuable pharmaceutical information—*Derwent Drug File* (Files 377/912 and 376/913) and *Derwent Biotechnology Abstracts* (File 357). Subject coverage is summarized in a chart included in the online version of the September *Chronolog*.

Derwent Drug File (F377/912/DDNS and 376/913/DDBF)

Derwent Drug file is a highly focused database of selected articles from 1,200 international pharmaceutical journals and conference reports. The database contains over 1.6 million references dating back to 1964. Files 377/912/DDNS cover the literature from 1983 to the present while Files 376/913/DDBF cover the literature from 1964 through 1982. *The Derwent Drug File* is an ideal database for both retrospective searches and for keeping up-to-date via weekly Alerts on all aspects of drug development, synthesis, evaluation, manufacture and use.

Subjects covered include:

Adverse effects	Interactions	Pharmacology
Analysis	Mechanisms of action	Toxicology
Animal studies	Medicinal chemistry	Treatment of diseases
Biochemistry	Metabolism	Trial preparations
Clinical studies	Pharmaceutics	
Drug comparisons	Pharmacokinetics	

Derwent Drug File offers you:

- Broad technology coverage
- Powerful drug-based indexing
- A unique combination of biological and chemical information—ideal for exploring all types of structure-activity relationships
- Around 50,000 records added to the database per year, each record intellectually selected for relevance
- A highly informative abstract for all records outlining research methods and detailing results and conclusions drawn

Derwent Biotechnology Abstracts (F357/DWBA)

Biotechnology is currently **the hot topic** in the pharmaceuticals industry! With *Derwent Biotechnology Abstracts* you won't waste time searching irrelevant biological information, because every abstract focuses specifically on processes and applications of biotechnology-related research. Use Alerts (updates every two weeks) to keep your users abreast of the latest developments and potential applications of biological systems to the pharmaceutical industry, medicine, pollution control and other commercial operations.

Pharmaceutical-relevant technologies covered include:

- Pharmaceuticals
- Genetic engineering, fermentation, recombinant production
- Cell culture
- Biochemical engineering
- Biocatalysts
- Purification and waste disposal

Derwent Biotechnology Abstracts offers you:

- Comprehensive coverage of over 1,200 international journals, conference proceedings, and patents from 40 issuing authorities—in one source back to 1982.
- Biweekly updates that allow you to monitor your competitor's activities in biotechnology around the world
- Clear, English-language summaries written by Derwent's biotechnology experts that enable users to focus easily on the biological content of every patent. ♦

MARTINDALE Reloaded on DataStar™

Martindale: The Complete Drug Reference (label: MART) was reloaded on DataStar this summer. Produced by the Royal Pharmaceutical Society of Great Britain, Martindale has been the reference source of choice for practicing pharmacists and physicians since 1883 when the first edition was published. MART is the online equivalent of the 32nd edition of Martindale, but unlike the hard-copy which is only re-released every few years, the database will be updated every quarter.

It provides reliable, unbiased, and evaluated information on drugs and medicines used throughout the world. Selected investigational and veterinary drugs, herbal medicines, pharmaceutical excipients, vitamins and nutritional agents, vaccines, radiopharmaceuticals, contrast media and diagnostic agents, medicinal gases, drugs of abuse and recreational drugs, toxic substances, disinfectants, and pesticides are also included, making Martindale an invaluable resource in all branches of pharmaceutical science. Martindale is regularly updated to ensure that it continues to meet the information requirements of practitioners of medicine and pharmacy. Information is derived from published sources and is presented as sections of text with supporting referenced abstracts and reviews.

The following information relating to drugs is covered:

- definitions and descriptions
- adverse effects and treatments
- precautions
- interactions
- pharmacokinetics
- uses
- administration
- trade names of preparation

Additionally, Martindale also contains *disease treatment summaries* that provide overviews of diseases and the choice of treatments available.

Details of commercial preparations from a wide range of countries are searchable by trade name with cross-references to monographs for their active ingredients where

fuller information is given. A directory of manufacturers of drug preparations worldwide, together with their addresses, is included.

While the hard-copy version is divided into 51 chapters—each of which brings together information on drugs and groups of drugs that have similar actions or uses—the reloaded DataStar database presents individual documents focusing on specific aspects of a drug (e.g. the precautions associated with Carbamazepine). However, the database has been designed in such a way as to make it simple to reconstruct a full description of that drug as it appears in the hard-copy (i.e. definition, adverse effects, precautions, uses and administration, etc.)

BizInt — Continued from page 9

literature databases on Dialog. You can define your own templates for different users or departments — focusing on the data of interest to R&D, legal, strategic planning, etc. Using the HTML export feature, you can present the results of searches or Alerts in a table with links to the full records and distribute it via e-mail or the web.

New for 2001 in both BizInt Smart Charts products is a statistics feature, which you can use to create Excel spreadsheets and graphs from any column in your chart. For example, you can analyze the number of patents by company or the number of compounds by indication. Also new for 2001 is support for the Prous Science Drug Data Report in BizInt Smart Charts for Pharmaceuticals, and the addition of several patent and medical literature databases (US Patents Fulltext, EMBASE, MEDLINE, and BIOSIS) in BizInt Smart Charts for Patents.

The best way to evaluate the value of BizInt Smart Charts is to try it on one of your own projects. You can download a fully functional trial version of either BizInt Smart Charts product from the BizInt Solutions web site.

All the component parts of an entire chapter of the hard-copy can be retrieved together: thus, should you want to see the equivalent of the entire chapter on Cardiovascular Drugs, you can do so easily—up until now, this has not been possible on DataStar. Equally, should you be interested in only a certain aspect of all the drugs with similar actions or uses (e.g. the pharmacokinetics of Lipid Regulating Drugs) the functionality of Martindale on DataStar allows you easily to retrieve just these sections.

Cross-references are made throughout the database allowing you to find out further information from related documents.

To increase ease of use, look-up lists of searchable terms will be made available on DataStarWeb and DataStar for Windows.

Continued on page 16

Databases supported

BizInt Smart Charts for Pharmaceuticals — DialogClassic and DialogClassic Web; DataStar and DataStarWeb

- PJB Pharmaprojects: 128,928; PHAR
- IMSworld R&D Focus: 445, 955; IPUR
- Adis R&D Insight: 107, 907; ADRD
- Prous Science Drug Data Report: 452, PRDR

BizInt Smart Charts for Patents — DialogClassic and DialogClassic Web

- Derwent World Patents Index: 280, 350, 351, 352
- IFI CLAIMS®/US Patents: 340, 341, 942
- US Patents Fulltext: 652, 653, 654
- EMBASE®: 72, 73
- MEDLINE®: 154, 155
- BIOSIS Previews®: 5, 55

Getting started with BizInt Smart Charts

For more information, including trial software and pricing information, visit <http://www.bizcharts.com>. Or contact Diane Webb, President, BizInt Solutions, 650 N. Costello Place, Orange, CA 92869 (714) 289-1000, dqw@bizcharts.com. To view examples of BizInt Smart Charts for Pharmaceuticals and for Patents, see the online version of the September *Chronolog* at <http://library.dialog.com/chron/2001/0009>.♦

Mergent™ Files Available Soon on Dialog

Mergent, a premier source of reliable business information, has provided Dialog with three new, exciting databases: File 555, Mergent™ Company Profiles (no access to U.S. customers) File 556, Mergent™ Company Snapshots File 557, Mergent™ Company News Reports

These databases replace the former Moody's files.

Mergent Company Profiles. File 555 provides descriptive and financial information on all major publicly held U.S. companies. The file covers all companies on the New York and American stock exchanges, NASDAQ National Market and Small Cap exchanges, as well as selected companies on regional exchanges, the OTC Bulletin Board and "Pink Sheets." Mergent Company Profiles contains background information on more than 9,000 companies of high investor interest. The data provides rich textual profiles including history, business, properties, subsidiaries, and a listing of executives. The database also contains "as presented financials" denoting the figures originally reported by the company in its document for both annual and quarterly financials. Basic company information for each record includes company name, address, telephone and fax numbers, web site address, and SIC codes. Sources for the data comprise 10Ks, 10Qs, annual reports, quarterly reports, news releases, prospectuses, and stock exchange bulletins. File 555 is available to customers outside North America.

Mergent Company Snapshots. File 556 provides descriptive and financial information on all major publicly-held U.S. companies. The file covers all companies on the New York and American stock exchanges, NASDAQ National Market and Small Cap exchanges, as well as selected companies on regional exchanges, the OTC Bulletin Board and "Pink Sheets." The data include concise narrative descriptions of the most essential company information plus three-year financial histories. The database pro-

vides basic company information and financials for 9,000 companies of high investor interest. File 556 is available to all Dialog customers.

Mergent Company News Reports. File 557 offers current, comprehensive coverage of business news and financial information on approximately 9,000 publicly-held U.S. corporations that include industrial companies, banks, savings and loan institutions, insurance companies, real estate companies, public utilities, and transportation companies. Also included are selected non-U.S. companies. Information for the file is taken from annual reports, quarterly reports, news releases, prospectuses, and newswire services. File 557 is available to all Dialog customers.

Search tips. Use CO= or /CO to locate the company of interest, e.g., SELECT CO= BERKSHIRE HATHAWAY? In Files 555 and 556 you can search the key financials using the following prefixes:

Total Revenue	SA=
Total Assets	TA=
Total Liabilities	TL=
Net Income	NL=
Long Term Debt	LD=

You can search the primary SIC code for a company using PC=, and secondary as well as the primary SIC codes are searchable using SC=, e.g., S SC=6331.

Bluesheets for all three databases can be found on the Dialog website at <http://library.dialog.com/bluesheets/>. Watch the Dialog online flash for the availability of the Mergent files. Enter HELP RATES XXX (where XXX is the file number) to find the file and full record pricing. ♦

CANCERLIT® Reloaded

CANCERLIT (Dialog: File 159, DataStar: CANC) has been reloaded to include the U.S. National Library of Medicine (NLM) revisions to the Medical Subject Headings (MeSH®) vocabulary. For the 2001 reload, citations going back to the earliest records from 1975 to the present have been updated wherever necessary with the new MeSH headings.

Changes to existing fields

Dialog:

- Volume, issue, page, and publication year are searchable in the Source Information (SO=) field.
- Subfile (SF=) field includes the description instead of 1-3 letter codes. For example: SF=D will be SF=DENTAL
SF=H will be SF=HEALTH
ADMINISTRATION
SF=IM will be SF=INDEX MEDICUS

DataStar:

- Tree Numbers now have zeros to make three digits (e.g., D2-241-81-407 must now be searched as D02-241-081-407)

New fields

- Dialog: Record Type (RT=). All records have RT=Completed.
DataStar: all records are searchable with the quick code COMPLETE=YES
- Dialog: Record Date Created (UP=).
DataStar: Entry Date (ED). This field displays the date when the record was entered into the database by the Information Provider.
- Dialog: PubMed Unique Identifier – PMID (AA=). This field is available this year for NLM records only. Other records will have this field added in 2002. On DataStar the PMID appears in the AN field.
- Country of Publication (Dialog: CP= DataStar: CP)

Fields no longer available:

Due to format changes Journal Announcement (Dialog's JA= and DataStar's IM) and ISBN (BN=) are no longer available from the Information Provider. Map CS has been eliminated on Dialog. ♦

Training Schedule

Training classes on Dialog's services are held throughout the world. For the most current schedule for all locations, check the Dialog Web site at http://training.dialog.com/sem_info/calendar/. To register, U.S. clients should call the Knowledge Center at 1-800-3DIALOG (800-334-2564).

Midwest

Chicago, IL

- 9/11 Developing Dialog Searching Expertise, Pt. 4: Power Searching
- 9/11 Special Topic
- 9/13 Business of Science
- 9/13 Developing Dialog Searching Expertise, Pts. 1 & 2: Fast Start and Intermediate
- 9/18 Biomedical Information Seminar
- 9/25 Developing Patent Research Expertise, Pt. 3: Prior Art
- 9/25 Developing Patent Research Expertise, Pt. 4: Competitive Intelligence
- 10/9 Asia-Pacific Corporate Intelligence
- 10/9 Chemical Searching for Non-Chemists
- 10/11 Company Intelligence
- 10/11 Market Intelligence
- 10/23 Engineering Information & Techniques
- 10/23 Intellectual Property: Trademarks & Copyright
- 10/25 Creating & Using Alerts
- 10/25 Fundraising with Dialog

Ypsilanti, MI

- 9/12 Developing Dialog Searching Expertise, Pt. 3: Advanced
- 9/12 Market Intelligence
- 10/24 Developing Patent Research Expertise, Pt. 2: Patent Families & Legal Status
- 10/24 Developing Dialog Searching Expertise, Pt. 4: Power Searching

St. Paul, MN

- 9/12 Special Topics on Dialog: Tips for Using DialogWeb
- 9/12 Special Topics on Dialog: Selecting the Correct Database
- 9/12 Developing Dialog Searching Expertise, Pts 1 & 2: Fast Start and Intermediate

Kansas City, MO

- 9/12 Asia-Pacific Corporate Intelligence
- 9/12 Company Intelligence

Columbus, OH

- 9/20 Dialog Regional Update
- 10/24 Developing Dialog Searching Expertise, Pts 1 & 2: Fast Start and Intermediate
- 10/24 Developing Patent Research Expertise, Pt. 2: Patent Families & Legal Status

South

Cary, NC

- 8/22 Developing Dialog Searching Expertise, Pts. 1 & 2: Fast Start and Intermediate
- 8/29 Developing Dialog Searching Expertise, Pt. 3: Advanced
- 8/29 Developing Dialog Searching Expertise, Pt. 4: Power Searching

West

Aurora, CO

- 9/27 Developing Dialog Searching Expertise, Pt. 4: Competitive Intelligence
- 9/28 Searching Dialog: The Basics
- 10/18 Company Intelligence
- 10/19 Market Intelligence

Inglewood, CA

- 9/20 Developing Dialog Searching Expertise, Pt. 1: Fast Start
- 9/20 Developing Dialog Searching Expertise, Pt. 2: Intermediate
- 9/21 Developing Patent Research Expertise, Pt.1: Patent Search Basics

- 9/21 Developing Patent Research Expertise, Pt. 3: Prior Art

Los Angeles, CA

- 10/25 Dialog Regional Update

Costa Mesa, CA

- 9/14 Developing Dialog Searching Expertise, Pt. 1: Fast Start
- 9/14 Developing Dialog Searching Expertise, Pt. 2: Intermediate

San Diego, CA

- 9/24 Developing Dialog Searching Expertise, Pt. 1: Fast Start
- 9/24 Developing Dialog Searching Expertise, Pt. 2: Intermediate
- 9/25 Developing Dialog Searching Expertise, Pt. 3: Advanced
- 9/25 Developing Dialog Searching Expertise, Pt. 4: Power Searching

San Francisco, CA

- 9/11 Developing Dialog Searching Expertise, Pt. 4: Power Searching
- 9/19 Developing Dialog Searching Expertise, Pts. 1 & 2: Fast Start and Intermediate
- 9/27 Developing Patent Research Expertise, Pt. 4: Competitive Intelligence
- 10/9 Pharmaceutical Business Searching
- 10/23 Dialog Regional Update
- 10/31 Developing Patent Research Expertise, Pt. 1: Patent Search Basics

Northeast

Boston, MA

- 9/10 Dialog Applications Briefing: Business & Science of Food
- 9/12 Developing Patent Research Expertise, Pt. 3: Prior Art
- 9/12 Developing Patent Research Expertise, Pt. 4: Competitive Intelligence
- 9/13 Developing Dialog Searching Expertise, Pts. 1 & 2: Fast Start and Intermediate
- 9/17 Creating & Using Alerts
- 9/19 Company Intelligence
- 9/19 Market Intelligence
- 9/24 Fundraising with Dialog
- 9/26 Intellectual Property: Trademarks & Copyright
- 9/27 Pharmaceutical Business Searching
- 9/27 Pharmaceutical Science Searching
- 10/10 Dialog Regional Update

New York, NY

- 10/12 Dialog Regional Update

Iselin, NJ

- 9/11 Dialog Pharmaceutical Forum

MARTINDALE — Continued from page 14

Other functionality like hyper-text linking will help users bring together related documents.

The reloaded Martindale database can be used to answer a wide variety of questions including:

- what are the adverse effects associated with Fluticasone Propionate?
- can antimuscarinic drugs be used in the treatment of gastro-intestinal disorders?
- what is the molecular formula of Benzhexol Hydrochloride?

- in Thailand, a preparation called Abacus is available; what is it, what are its properties, who manufactures it, and what is it used to treat?
- are there any drugs which are useful in the treatment of hiccups?
- what are the constituent ingredients of the preparation Arelcant?
- what preparations are marketed by GlaxoSmithKline in Hong Kong?

Pricing remains unchanged: SFr 87 (US\$ 60) per connect hour, SFr 1-80 (US\$ 1-24) per document displayed. ♦